Nippon Shinyaku Co. Ltd.

06/24/2024 | Press release | Distributed by Public on 06/24/2024 01:04

Japan’s PMDA approves Antineoplastic Agent 'Jaypirca® 50 mg and 100 mg tablets' for Patients with Relapsed or Refractory MCL Who are Resistant or Intolerant to Other BTK Inhibitors